ERGIDINA Trademark

Trademark Overview

On Monday, June 15, 2009, a trademark application was filed for ERGIDINA with the United States Patent and Trademark Office. The USPTO has given the ERGIDINA trademark a serial number of 79070249. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Saturday, June 15, 2019. This trademark is owned by ADIENNE SRL. The ERGIDINA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products, namely, antibody for treatment of rare diseases
ergidina

General Information

Serial Number79070249
Word MarkERGIDINA
Filing DateMonday, June 15, 2009
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateSaturday, June 15, 2019
Registration Number3790417
Registration DateTuesday, May 18, 2010
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 2, 2010

Trademark Statements

Goods and ServicesPharmaceutical products, namely, antibody for treatment of rare diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeH - NOT AVAILABLE
Class Status DateSaturday, June 15, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameADIENNE SA
Party Type31 - New Owner After Registration
Legal Entity Type98 - Unknown
AddressLugano CH6900
CH
Party NameADIENNE SRL SU
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressIT
Party NameADIENNE SRL
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressIT
Party NameADIENNE SRL
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressIT

Trademark Events

Event DateEvent Description
Thursday, January 16, 2020NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Thursday, January 16, 2020DEATH OF INTERNATIONAL REGISTRATION
Saturday, May 18, 2019COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Wednesday, June 17, 2015NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Wednesday, June 17, 2015REGISTERED-SEC.71 ACCEPTED
Wednesday, June 17, 2015CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Friday, May 22, 2015TEAS SECTION 71 RECEIVED
Friday, May 22, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, March 19, 2015CHANGE OF OWNER RECEIVED FROM IB
Thursday, October 30, 2014CHANGE OF NAME/ADDRESS REC'D FROM IB
Sunday, March 31, 2013FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, August 31, 2010FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, August 31, 2010FINAL DISPOSITION PROCESSED
Wednesday, August 18, 2010FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, May 18, 2010REGISTERED-PRINCIPAL REGISTER
Tuesday, March 2, 2010PUBLISHED FOR OPPOSITION
Wednesday, February 10, 2010NOTICE OF PUBLICATION
Saturday, January 23, 2010LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, January 13, 2010APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, December 14, 2009TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, December 14, 2009CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 14, 2009ASSIGNED TO LIE
Thursday, November 26, 2009TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, October 16, 2009REFUSAL PROCESSED BY IB
Tuesday, September 22, 2009NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, September 22, 2009REFUSAL PROCESSED BY MPU
Tuesday, September 22, 2009NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, September 21, 2009NON-FINAL ACTION WRITTEN
Tuesday, September 15, 2009ASSIGNED TO EXAMINER
Tuesday, July 28, 2009APPLICATION FILING RECEIPT MAILED
Friday, July 24, 2009NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, July 23, 2009SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

ergidina rare diseases treatment antibody products namely pharmaceutical